Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Nab-paclitaxel · Abraxane, Paclitaxel

Small molecule · Inhibitor of Tubulin (TUBB) · developed by Bristol-Myers

Approved FDA, Jan 2005
BMY Developer
25 Registered trials

What is Nab-paclitaxel?

Nab-paclitaxel is an albumin-bound nanoparticle formulation of the taxane paclitaxel, a microtubule inhibitor that binds tubulin, promotes microtubule assembly and prevents their depolymerization, disrupting mitosis and cell division. It is used in cancers including metastatic breast cancer, non-small cell lung cancer, pancreatic adenocarcinoma, and is studied in sarcoma, renal cancer, and other solid tumors and lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Abraxane, Paclitaxel, RO0247506, ABI-007, Paclitaxel-albumin, Albumin-Bound Paclitaxel, Nanoparticle Albumin-bound Paclitaxel
Drug type
Small molecule
Targets
Tubulin (TUBB)
Mechanism
Inhibitor of Tubulin (TUBB)
Pathways
microtubule assembly and stabilization, mitosis, inhibition of microtubule dynamics
Therapy area
Oncology
Developer
Bristol-Myers (BMY)
Also in trials of
AAPG, ABBV, ACTU, AGEN, AZN, CHRS, CORT, EIKN, FTH, GILD
FDA status
Approved as Abraxane, Paclitaxel (January 7, 2005), NDA021660 · FDA label
UNII
PF4ZJ19BNY

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 31, 2022). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07365319 Phase 2/3 Non Small Cell Lung Cancer (Squamous or Non Squamous) Recruiting EIKN
NCT07063745 Phase 2/3 Metastatic Non-small Cell Lung Cancer With MTAP Deletion Recruiting BMY
NCT07060807 Phase 3 Breast Neoplasms Recruiting MRK
NCT06103864 Phase 3 Breast Cancer Recruiting AZN
NCT05257408 Phase 3 Ovarian Neoplasm Active not recruiting CORT
NCT04329949 Phase 3 Metastatic Pancreatic Ductal Adenocarcinoma Terminated CORT
NCT03520686 Phase 3 Non Small Cell Lung Cancer Terminated IBRX
NCT07234877 Phase 2 Non Small Cell Lung Cancer Not yet recruiting SMMT
NCT07769502 Phase 2 Pancreatobiliary Cancers Recruiting ABBV
NCT05632328 Phase 2 Advanced Pancreatic Ductal Adenocarcinoma Active not recruiting AGEN
NCT07280377 Phase 1/2 Anal Cancer Metastatic Active not recruiting ONCY
NCT04827953 Phase 1/2 Pancreatic Ductal Adenocarcinoma Active not recruiting AGEN
NCT04643405 Phase 1/2 Advanced Pancreatic Cancer Terminated AAPG
NCT04390399 Phase 2 Pancreatic Cancer Active not recruiting IBRX
NCT04396821 Phase 1/2 Advanced Cancer Active not recruiting BMY
NCT04198766 Phase 1/2 Solid Tumor Recruiting INBX
NCT03645928 Phase 2 Metastatic Melanoma Terminated IOVA
NCT03910387 Phase 2 Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed LXRX
NCT03678883 Phase 2 Cancer Active not recruiting ACTU
NCT03424005 Phase 1/2 Metastatic Breast Cancer Recruiting GILD
NCT02762981 Phase 1/2 Solid Tumors Completed CORT
NCT07488884 Phase 1 Pancreatic Cancer Resectable Withdrawn IBRX
NCT05300048 Phase 1 Advanced Solid Tumor Terminated FTH
NCT04336098 Phase 1 Advanced Solid Tumor Completed CHRS
NCT04060342 Phase 1 Pancreatic Adenocarcinoma Terminated GOSS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first (first 25).

Conditions studied

CancerMetastatic Breast CancerNeoplasm MetastasisNeoplasm of BoneNeoplasm of LungNeoplasm, BreastNeoplasms,ColorectalPancreatic AdenocarcinomaPancreatic CancerRefractory CancerRefractory NeoplasmRefractory Non-Hodgkin LymphomaRenal CancerResistant Cancer

Other drugs acting on TUBB

Sabizabulin Phase 3

More from Bristol-Myers

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved Xanomeline FDA approved

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Nab-paclitaxel

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.